Relative risk of hemorrhage during pregnancy in patients with brain arteriovenous malformations

How to cite:

Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.1177/1747493017694387

© 2017 World Stroke Organization

Version: Accepted Manuscript

Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online's data policy on reuse of materials please consult the policies page.
Relative Risk of Hemorrhage during Pregnancy in Patients with Brain Arteriovenous Malformations

Janneke van Beijnum PhD,1,7 Tim Wilkinson MRCP,3 Heather J. Whitaker PhD,4 Johanna G. van der Bom PhD,8 Ale Algra PhD,1,2 W. Peter Vandertop PhD,5 René van den Berg PhD,6 Patrick A. Brouwer MD,9 Gabriël J.E. Rinkel PhD,1 L. Jaap Kappelle PhD,1 Rustam Al-Shahi Salman PhD 3 for the Scottish Audit of Intracranial Vascular Malformations collaborators,* Catharina J.M. Klijn PhD1

Department of Neurology and Neurosurgery,1 Brain Center Rudolf Magnus, and the Julius Centre for Health Science and Primary Care,2 all at the University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands
Division of Clinical Neurosciences,3 Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, United Kingdom
Department of Mathematics and Statistics,4 The Open University, Walton Hall, Milton Keynes MK7 6AA, United Kingdom
Department of Neurosurgery5 and Radiology,6 Neurosurgical Center Amsterdam, VU University Medical Center and Amsterdam Medical Center, Amsterdam, P.O. Box 7057, 1007 MB, The Netherlands
Department of Neurosurgery,7 Clinical Epidemiology,8 and Radiology,9 Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands

CONTRIBUTIONS
JvB, TW, WV, PB, GR, LR, RA-SS, and CK were involved in the design of the study. JvB, RA-SS, and TW collected data. JvB, HW, JvdB, and AA were involved in the statistical analyses. JvB drafted the paper, and all co-authors reviewed and approved the final version.

CORRESPONDING AUTHOR
Janneke van Beijnum
Department of Neurosurgery
University Hospital of Wales
Heath Park
Cardiff CF14 4XW
Tel +44 29 2074 5015
Fax + 44 29 2074 2560
Email J.vanBeijnum@gmail.com

WORD COUNT
2,510 (manuscript)

KEYWORDS
Arteriovenous malformation – Intracranial hemorrhage - Pregnancy - Self-controlled case-series

* Collaborators are listed in Online Supplement.
ABSTRACT

Background – It is unclear whether the risk of bleeding from brain arteriovenous malformations (BAVMs) is higher during pregnancy, delivery or puerperium. We compared occurrence of BAVM hemorrhage in women during this period with occurrence of hemorrhage outside this period during their fertile years.

Methods – We included all women with ruptured BAVMs (16-41 years) from a retrospective database of patients with BAVMs in four Dutch university hospitals (n=95) and from the population-based Scottish Audit of Intracranial Vascular Malformations (n=44). We estimated the relative rate of BAVM rupture (before any treatment) during exposed time (pregnancy, delivery, puerperium) versus non-exposed time during fertile years, using the case-crossover design as primary analysis, and the self-controlled case-series design as secondary analysis.

Results – In 17 of 95 Dutch women and in 3 of 44 Scottish women, hemorrhages occurred while pregnant; none occurred during delivery or puerperium. In Dutch women, the relative rate of BAVM rupture during pregnancy, delivery, or puerperium was 6.8 (95% confidence interval [CI] 3.6-13) according to the case-crossover method and 7.1 (95%CI 3.4-13) using the self-controlled case-series method. In Scottish women, the relative rate was 1.3 (95%CI 0.39-4.1) using the case-crossover method and 1.7 (95%CI 0.0-4.4) according to the self-controlled case-series method. Because of limited overlap of CIs we refrained from pooling the cohorts.

Conclusions – Case-crossover and self-controlled case series analyses reveal an increase in relative rate of brain AVM rupture during pregnancy in the Dutch cohort but not in the Scottish cohort. Since point estimates varied between both cohorts and numbers are relatively small, the clinical implications of our findings are uncertain.
Brain arteriovenous malformations (BAVMs) are abnormal connections between arteries and veins leading to arteriovenous shunting with an intervening network of vessels – the so-called nidus – and without a true capillary bed. The most frequent presentation of BAVMs is intracranial hemorrhage, which has a peak incidence in the third and fourth decade. Various case-reports and case-series of patients with BAVMs have reported the occurrence of hemorrhage during pregnancy. One study on natural history reported that one in four women aged between 20 and 29 years, presenting with hemorrhage, were pregnant. Some studies have suggested that women have an increased risk of hemorrhage during pregnancy, whereas another study did not. Investigating the effect of transient exposures such as pregnancy is methodologically challenging. Most previous studies compared hemorrhages rates during pregnant, and non-pregnant follow-up, often in selected patient groups such as women referred for radiosurgery. In the past, incorrect interpretation of retrospective data in one study has led to recommendations to sterilize women with BAVMs. The effect of transient exposures on acute events can be studied with self-controlled methods, which use patients as their own controls in order to ascertain whether there is an association between a transient exposure and the acute event. Thus, confounding by variation in patients’ characteristics can be avoided. By means of two different self-controlled methods, we investigated in women with a ruptured BAVM whether the relative chance of rupture is higher during pregnancy, delivery, and puerperium than outside this period.
METHODS

We estimated the relative rate of BAVM hemorrhage during pregnancy, delivery, and puerperium using a case-crossover design (Supplementary Figure I) as primary analysis, and according to the self-controlled case-series method (Supplementary Figure II) as secondary analysis. Only the first BAVM hemorrhage during untreated follow-up was used (Supplementary Figures I and II). In both analyses we assumed a nine-month period (from the 7th week after conception through the 6th week after delivery) for the time at risk during pregnancy, delivery, and puerperium. The first six weeks of pregnancy were excluded because the hemodynamic changes in relation to pregnancy are less prominent during this time. Only the first BAVM hemorrhage during untreated follow-up was used in both analyses (Supplementary Figures I and II).

PATIENTS

We included all women with BAVM hemorrhage at fertile age (i.e. from 16 years up to and including 41 years), who were seen in one of four Dutch university hospitals (VUMC Amsterdam, AMC Amsterdam, Leiden UMC, and UMC Utrecht; inclusion period 1990-2006), or who were included in the population-based Scottish Audit of Intracranial Vascular Malformations study (SAIVMs; inclusion periods 1999-2003 and 2006-2010). The women in the Dutch hospitals were retrospectively identified through multiple, overlapping registries in each hospital to ensure that no patients were missed: stroke registries, diagnosis registration systems, pathology registries, operation registries, registries of embolized and radiosurgically treated patients, and neurovascular meetings. The SAIVMs is an on-going National Health Service clinical audit of adults who were aged 16 years or older and were resident in Scotland when
first diagnosed with any type of intracranial vascular malformation. The Scottish Intracranial Vascular Malformations Study (SIVMS) is a prospective, population-based cohort study in which anonymous data extracts from SAIVMs are used. Patients were identified through multiple overlapping sources of case ascertainment, which included a Scotland-wide collaborative network of neurologists, neurosurgeons, stroke physicians, radiologists, and pathologists, and central registers of hospital discharge records and death certificates.(15) The fertile period was defined from 16 years up to and including 41 years because in the general population 99% of pregnancies occur in women in this age range (Statistics Netherlands, [www.statline.cbs.nl](http://www.statline.cbs.nl)). The diagnosis of BAVM was confirmed with radiological or pathological examination. Patients who were diagnosed with hereditary hemorrhagic telangiectasias were excluded. BAVM hemorrhage was defined as a symptomatic clinical event, with signs of intracranial blood on brain imaging performed at the time of symptoms, lumbar puncture, or on post-mortem examination referable to the BAVM or an associated, flow-related aneurysm. All hemorrhages were classified as having occurred either during pregnancy, delivery, or puerperium, or outside this period. In patients with a hemorrhage during pregnancy, delivery, or puerperium, we retrieved information on maternal age, gestational age at the time of hemorrhage, mode of delivery, location and treatment of the BAVM, and maternal (according to the Glasgow Outcome Scale(16)) and fetal outcome.

**Maternity Data**

For women in the Dutch cohort, we used information regarding live-born children that was given by patients who participated in a survey to investigate familial occurrence of BAVMs,(17) and information retrieved from the medical files.
For women in the Scottish cohort, obstetric episodes were obtained from the maternity inpatient, and day-case discharges data set by the Information Services Division (ISD) in the Scottish Morbidity Records (SMR02). The ISD has consistently achieved a national coverage of 98% of all births (www.isdscotland.org/Health-Topics/Maternity-and-Births/Births/). The SMR02 maternity data were cross-checked with any information about previous pregnancies in the case records of the women. If a patient, who met the inclusion criteria, did not link with the SMR02 dataset her case records were searched for references to any children or previous pregnancies. In most cases, these women had never been pregnant. For the women who did not link with the SMR02 dataset, and whose case records suggested existing children, the patient or her GP was contacted and asked to provide the delivery dates and gestations of her children.

In both Dutch and Scottish women abortions and miscarriages were not taken into account.

**Statistical Analysis**

First, we estimated the relative hemorrhage rates during pregnancy, delivery, or puerperium, and during non-exposed time, restricting the duration of follow-up to the time until the first hemorrhage, for the total cohort and the Dutch and Scottish cohorts separately. Subsequently, the relative rate of BAVM hemorrhage during pregnancy, delivery, and puerperium was estimated using the case-crossover design as primary analysis, and the self-controlled case-series method as secondary analysis.(12-14) We planned to analyze the Dutch and Scottish cohorts separately, and subsequently combined.

In the case-crossover analysis (**Supplementary Figure I**), we expressed the time at risk of a woman until occurrence of her first hemorrhage during her fertile years in “9-
months’ periods” by multiplying the number of years by 12/9 yielding relative rates with 95% confidence intervals (CIs). Analyses were performed with SPSS (version 20).

In the self-controlled case-series analysis (Supplementary Figure II), we studied the first hemorrhage because hemorrhage may affect subsequent exposure (e.g. a woman may die after hemorrhage or may be advised against pregnancy). We used the extension to the self-controlled case-series method for censored, perturbed or curtailed post-event exposures to obtain unbiased relative rate estimates.(14) Analyses were performed using STATA (Version 8.1). CIs were estimated using bootstrapping.

**Review of the literature**

We searched PubMed for case-series and systematic reviews reporting on women with BAVMs and their hemorrhage risk during pregnancy, delivery, and puerperium published in English on September 1st, 2016, with the search terms (intracranial arteriovenous malformations OR brain arteriovenous malformations) AND intracranial hemorrhage AND pregnancy.

**Ethical approval**

The Dutch study was approved by the institutional ethical committee of the University Medical Center Utrecht.(17) The Multicenter Research Ethics Committee for Scotland (MREC/98/0/48) and the Fife and Forth Valley Research Ethics Committee (08/S0501/76) approved the under taking of observational studies (to which an opt-out consent policy applied) and postal questionnaire studies (which required opt-in consent).
RESULTS

In 95 (28%) of 340 women in the Dutch and in 44 (22%) of 202 women in the Scottish cohort, hemorrhage occurred during their fertile lives (Table 1).

With respect to case-ascertainment in the Scottish cohort, three patients were reported by ISD only and not by one of the Scottish neuroscience centers. One of these three women experienced BAVM hemorrhage during her pregnancy (Table 2).

On average, women in the Dutch cohort were slightly older than women in the Scottish cohort (observed difference 3.0 years, 95%CI 0.62-5.4) at the time they gave birth to their first child. The proportion of lobar BAVMs was higher in the Scottish cohort (observed difference 21%, 95%CI 4.6-38).

**Dutch cohort**

Seventeen women experienced BAVM hemorrhage during 56 years at risk (relative hemorrhage rate 30%/year, 95%CI 18-49%), and in 78 women BAVM rupture occurred during 1,231 non-pregnant person years (relative hemorrhage rate 6.3%/year, 95%CI 5.0-7.9%). The case-crossover method yielded a relative rate during pregnancy, delivery, or puerperium of 6.8 (95%CI, 3.6-13), and the self-controlled case-series of 7.1 (95%CI, 3.4-13).

**Scottish cohort**

Three women experienced a hemorrhage during a total of 35 years at risk (relative hemorrhage rate 8.6%/year, 95%CI 1.8-25%), and 41 hemorrhages occurred during 597 non-pregnant person years (relative hemorrhage rate 6.9%/year, 95%CI 4.9-9.3%). The case-crossover method yielded a relative rate during pregnancy, delivery, or puerperium of 1.3 (95%CI, 0.39-4.1), and the self-controlled case-series a relative rate of 1.7 (95%CI, 0.0-4.4).
Combined cohort

Given the limited overlap of the CIs of the point estimates, we refrained from pooling both cohorts.

Review of the literature

We identified five case-series(8-11,18) and two systematic reviews (Table 3).(4,19) Two narrative reviews were excluded.(20,21) The most recent case-series – using a self-controlled method in large hospital-based, retrospective Chinese cohort – showed a decreased hemorrhage risk associated with pregnancy, delivery, and puerperium.(19) Another retrospective study concluded that the hemorrhage risk during pregnancy was not increased,(11) whereas two studies showed an increased risk of BAVM hemorrhage during pregnancy(9) or during the second trimester only.(10)
DISCUSSION

In the Dutch hospital cohort of women with a ruptured BAVM the relative rupture rate was approximately seven times higher during pregnancy, delivery, and puerperium than outside this period. The analyses in the smaller population-based Scottish cohort did not confirm this increased risk. Limited overlap of the CIs of the point estimates hampered the pooled analysis.

The observed difference in hemorrhage risk during pregnancy, delivery and puerperium between the Dutch and Scottish cohorts may have been due to chance, especially given the sample sizes. Still, referral bias may have played a role. One would think that a woman with BAVM hemorrhage is more likely to get referred to a neuroscience center if she is pregnant. Yet, one Scottish woman who experienced a BAVM hemorrhage during pregnancy was only reported to the researchers by the ISD but not by one of the collaborating neuroscience centers. In the Netherlands, we would expect that all young women with BAVM hemorrhage are referred to a neurosurgical center unless they have died in a local hospital. Geographic or ethnic differences are unlikely to explain the disparate risk during pregnancy, delivery and puerperium as both in The Netherlands and Scotland, the large majority of the women were Caucasian. Moreover, hemorrhage rates outside pregnancy were similar in both cohorts (6.3%/year vs. 6.9%/year), which makes it also unlikely that the higher proportion of women with lobar BAVMs included in the Scottish cohort explains the observed difference in hemorrhage risk during pregnancy.

A recent Chinese hospital-based study showed a decreased hemorrhage risk during pregnancy using the case-crossover method.(18) In this study, the relative hemorrhage rate during pregnancy, delivery and puerperium (2.7, 12
hemorrhages/452 pregnancies; Supplementary Figure III) was remarkably low in comparison to the Dutch (18, 17 hemorrhages/95 pregnancies) and to the Scottish (6.8, 3 hemorrhages/44 pregnancies) cohort. The relative hemorrhage rate outside pregnancy was also lower (4.1%/year) in the Chinese study than in the Dutch (6.3%/year) and Scottish (6.9%/year) cohorts. The Chinese women were enrolled over a large time frame between 1960 and 2010, and diagnosis of both hemorrhage and BAVM is likely to have been less accurate in the earlier decades. Also, the fact that the authors included 54 patients with previous hemorrhage or BAVM treatment may have influenced their hemorrhage risk as well as the decision to become pregnant in some women, and therefore biased their results.(18) Another study, which analyzed the effect of pregnancy using Cox proportional hazards regression modelling with pregnancy as time-dependent co-variable, yielded an almost eight times increased risk of BAVM hemorrhage during pregnancy.(9) This is comparable to the results found in the Dutch cohort.

An important strength of our study is that we used two self-controlled methods(12-14) which yielded similar results. We added the self-controlled case-series as a secondary analysis because of increased power in comparison to the case-crossover design, and the possibility to explicitly control for age- and time-related effects.(14) Additionally, we censored women at the time of first hemorrhage because the rupture rate increases after a first hemorrhage, and the occurrence of BAVM hemorrhage may influence the decision to become pregnant. Moreover, our cohorts were not limited to patients who were referred for a certain treatment as in some previous studies,(10,11) and we calculated the risk-time from the age of 16 years and not from birth.(11)
Our study is limited by the small number of included women despite our efforts to improve power by combing cohorts. Secondly, case-ascertainment differed between the Dutch and Scottish cohorts, which could have contributed to the different results during pregnancy. Thirdly, in both cohorts pregnant follow-up may have been underestimated by not including abortions and miscarriages. Additionally, pregnancies may have been missed by the ISD in Scotland, and the Dutch women might not have declared all of their pregnancies when asked. Finally, an important limitation of our study with respect to clinical applicability is that with the data we had we could calculate relative but no absolute risks of rupture during pregnancy, delivery, and puerperium. Moreover, risks for women with unruptured BAVMs cannot be deducted from our results. It is important to realize that all women included in our study bled, and that in the majority of women hemorrhage was the first presentation of their BAVMs (95% Dutch cohort, 98% Scottish cohort; Table 1).

Although our study cannot provide the final answers, which are needed for clinical practice, the results from the Dutch cohort support previous observations that the period of pregnancy, delivery and puerperium could increase the risk of BAVM rupture in particular with increasing gestational age. Women with a BAVM should be informed of the possibility that pregnancy probably increases the risk of BAVM hemorrhage, but that the extent to which this occurs is uncertain. Given the annual hemorrhage risk of 2.3-3.0% per year,(22,23) a temporary increase during pregnancy by ~ 1.5 as found in the Scottish cohort would not infer a considerably larger risk whereas an increase by ~ 7 would denote a clinically significant increased hemorrhage risk. Whether or not an unruptured BAVM should be treated before conception will depend on the characteristics of the BAVM, the individualized estimated risk of hemorrhage and treatment, and the informed opinion of the patient.
The short-term results of the ARUBA trial - showing a more than three-fold increased risk of stroke and death after intervention compared with conservative management in patients with unruptured BAVMs – have to be taken into account as well as the criticisms with respect to the conduct and outcome of this trial.(24,25) In our view, there is no reason to advise discontinuation of pregnancy or sterilization as has been done in the past.

Ideally, the effect of pregnancy on the hemorrhage risk of BAVMs should be investigated by the conduct of large multi-center prospective population-based studies because these will provide absolute risks during pregnancy for all women with BAVMs. Meanwhile, replication of this study design in larger prospectively population-cohorts or individual patient data meta-analysis studies can add to the current findings.
Funding Janneke van Beijnum was funded by the Netherlands Organization for Scientific Research and the Netherlands Heart Foundation (grant number 2002B138). Rustam Al-Shahi Salman was funded by the UK Medical Research Council, Chief Scientist Office of the Scottish Government, and UK Stroke Association. Catharina Klijn was funded by the Netherlands Heart Foundation (Clinical Established Investigator Grant 2012T077) and the Netherlands Organization for Scientific Research (ZonMw, Aspasia grant 015008048). The sponsors had no role in the study design, data collection, data analyses, data interpretation or writing of the report.

Conflict of interests P.A. Brouwer (Stryker, honoraria and consultant/advisory relationship; modest). The other authors declare no conflicts of interest.
REFERENCES


(14) Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored, perturbed, or curtailed post-event exposures. *Biostatistics* 2009;10:3-16.


Table 1 Baseline characteristics of 139 women with rupture from BAVMs at fertile age

<table>
<thead>
<tr>
<th></th>
<th>Dutch Cohort</th>
<th>Scottish Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of patients</strong></td>
<td>95</td>
<td>44</td>
</tr>
<tr>
<td>Initial BAVM presentation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ruptured</td>
<td>90 (95%)</td>
<td>43 (98%)</td>
</tr>
<tr>
<td>Unruptured</td>
<td>5 (5.3%)</td>
<td>1 (2.3%)</td>
</tr>
<tr>
<td><strong>Age at first hemorrhage (years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>29 (7.3)</td>
<td>30 (7.7)</td>
</tr>
<tr>
<td><strong>Age at birth of first child (years)</strong></td>
<td>n = 48</td>
<td>n = 27</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>26 (4.7)</td>
<td>23 (5.4)</td>
</tr>
<tr>
<td><strong>Number of pregnancies at first hemorrhage</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>51 (54%)</td>
<td>19 (43%)</td>
</tr>
<tr>
<td>1</td>
<td>21 (22%)</td>
<td>9 (21%)</td>
</tr>
<tr>
<td>2</td>
<td>18 (19%)</td>
<td>11 (25%)</td>
</tr>
<tr>
<td>3</td>
<td>4 (4.2%)</td>
<td>5 (11%)</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>1 (1.1%)</td>
<td>0</td>
</tr>
<tr>
<td><strong>BAVM Location</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lobar</td>
<td>49 (52%)</td>
<td>32 (73%)</td>
</tr>
<tr>
<td>Deep</td>
<td>27 (28%)</td>
<td>8 (18%)</td>
</tr>
<tr>
<td>Infratentorial</td>
<td>19 (20%)</td>
<td>4 (9.1%)</td>
</tr>
</tbody>
</table>

*Cumulative number of previous pregnancies (including current pregnancy if BAVM rupture occurred during pregnancy) prior to the date of first-ever BAVM hemorrhage.
<table>
<thead>
<tr>
<th></th>
<th>Age</th>
<th>G/P</th>
<th>GA</th>
<th>Location BAVM</th>
<th>Delivery</th>
<th>Treatment BAVM</th>
<th>Maternal outcome</th>
<th>Child’s outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dutch cohort</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>30</td>
<td>G1P0</td>
<td>34</td>
<td>Thalamus R</td>
<td>CS</td>
<td>SRS1</td>
<td>GOS 5</td>
<td>Healthy</td>
</tr>
<tr>
<td>2</td>
<td>30</td>
<td>G1P0</td>
<td>27</td>
<td>Frontal R</td>
<td>Vaginal</td>
<td>Excision</td>
<td>GOS 5</td>
<td>Healthy</td>
</tr>
<tr>
<td>3</td>
<td>33</td>
<td>G3P2</td>
<td>41</td>
<td>Parietal R</td>
<td>CS</td>
<td>Embolization, RS</td>
<td>GOS 5</td>
<td>Healthy</td>
</tr>
<tr>
<td>4</td>
<td>32</td>
<td>G1P0</td>
<td>32</td>
<td>Parietal L</td>
<td>CS</td>
<td>Excision</td>
<td>GOS 4</td>
<td>Healthy</td>
</tr>
<tr>
<td>5</td>
<td>27</td>
<td>G3P2</td>
<td>20</td>
<td>Mesencephalon L</td>
<td>CS</td>
<td>SRS</td>
<td>GOS 4</td>
<td>Healthy</td>
</tr>
<tr>
<td>6</td>
<td>25</td>
<td>G1P0</td>
<td>38</td>
<td>Temporal R</td>
<td>CS</td>
<td>Excision</td>
<td>GOS 5</td>
<td>Healthy</td>
</tr>
<tr>
<td>7</td>
<td>29</td>
<td>G1P0</td>
<td>24</td>
<td>Corpus callosum R</td>
<td>CS</td>
<td>SRS</td>
<td>GOS 5</td>
<td>Healthy</td>
</tr>
<tr>
<td>8</td>
<td>19</td>
<td>G1P0</td>
<td>22</td>
<td>Occipital L</td>
<td>CS</td>
<td>SRS</td>
<td>GOS 5</td>
<td>Healthy</td>
</tr>
<tr>
<td>9</td>
<td>18</td>
<td>G1P0</td>
<td>24</td>
<td>Frontal L</td>
<td>CS</td>
<td>SRS</td>
<td>GOS 5</td>
<td>Healthy</td>
</tr>
<tr>
<td>10</td>
<td>25</td>
<td>G1P0</td>
<td>24</td>
<td>Cerebellum R</td>
<td>U</td>
<td>SRS</td>
<td>GOS 5</td>
<td>Healthy</td>
</tr>
<tr>
<td>11</td>
<td>34</td>
<td>G2P1</td>
<td>12</td>
<td>Multilobar L</td>
<td>Vaginal</td>
<td>SRS</td>
<td>GOS 3</td>
<td>Healthy</td>
</tr>
<tr>
<td>12</td>
<td>24</td>
<td>G1P0</td>
<td>31</td>
<td>Parietal L</td>
<td>CS</td>
<td>Partial Excision, SRS</td>
<td>GOS 5</td>
<td>Healthy</td>
</tr>
<tr>
<td>13†</td>
<td>33</td>
<td>G2P1</td>
<td>28</td>
<td>Paraventricular R</td>
<td>CS</td>
<td>SRS</td>
<td>GOS 3</td>
<td>Healthy</td>
</tr>
<tr>
<td>14</td>
<td>33</td>
<td>G2P1</td>
<td>33</td>
<td>Basal ganglia R</td>
<td>CS</td>
<td>None</td>
<td>GOS 1</td>
<td>Healthy</td>
</tr>
<tr>
<td>15</td>
<td>35</td>
<td>G1P0</td>
<td>28</td>
<td>Frontal L</td>
<td>Vaginal</td>
<td>Excision</td>
<td>GOS 5</td>
<td>Healthy</td>
</tr>
<tr>
<td>16</td>
<td>22</td>
<td>G1P0</td>
<td>23</td>
<td>Frontal R</td>
<td>Vaginal</td>
<td>Excision</td>
<td>GOS 5</td>
<td>Healthy</td>
</tr>
<tr>
<td>17</td>
<td>24</td>
<td>G1P0</td>
<td>28</td>
<td>Occipital L</td>
<td>CS</td>
<td>Excision</td>
<td>GOS 5</td>
<td>Healthy</td>
</tr>
<tr>
<td>Scottish Cohort</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>34</td>
<td>G2P1</td>
<td>30</td>
<td>Multilobar R</td>
<td>CS</td>
<td>Excision</td>
<td>GOS 4</td>
<td>Healthy</td>
</tr>
<tr>
<td>2</td>
<td>26</td>
<td>G2P1</td>
<td>22</td>
<td>Multilobar L</td>
<td>U</td>
<td>Excision</td>
<td>GOS 4</td>
<td>IUFD</td>
</tr>
<tr>
<td>3‡</td>
<td>30</td>
<td>G1P0</td>
<td>7</td>
<td>Insula L</td>
<td>CS</td>
<td>SRS</td>
<td>GOS 4</td>
<td>Healthy</td>
</tr>
</tbody>
</table>

CS, Caesarean section; G, Gravidity; GA, Gestational age in weeks; GOS, Glasgow Outcome Scale; P, Parity; SRS, Stereotactic radiosurgery; U, Unknown; IUFD, Intrauterine Fetal Death.

* Excluded from the secondary analysis because the exact date of birth of her first child was unknown which was mandatory for the self-controlled case series but not for the case-crossover design.

† Second hemorrhage is not included in the analyses.

‡ ISD notification only.
### Hemorrhage Risk of Brain AVMs during Pregnancy

<table>
<thead>
<tr>
<th>Author</th>
<th>Study population</th>
<th>Methods and analysis</th>
<th>Results</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robinson et al. (1974)</td>
<td>Hospital-based retrospective case-series</td>
<td>Comparison of causative vascular lesion in Group 1 (presented &lt;2 yrs after pregnancy, delivery, or puerperium, or if pregnancy followed ≤2 yrs after presentation) and Group 2 (not associated with pregnancy).</td>
<td>Follow-up in 146 pts (96%). Group 1 (67 pts) included 24 pts (36%) with AVMs and 43 (64%) pts with aneurysms. 21/24 BAVM pts presented with SAH, and 11/21 pts bled during pregnancy. 47 pregnancies occurred in BAVM pts resulting in 35 live-born children. Group 2 (79 pts) included 9 patients (11%) with BAVMs and 70 (89%) with aneurysms. Only 1/9 BAVM pts presented with SAH. Hemorrhage usually occurred between weeks 16-24, shortly before labor, during delivery, or in early puerperium.</td>
<td>BAVMs were diagnosed in 36% of women who presented in association with pregnancy, which was 4 times higher than the overall numbers (9%). A BAVM pt who never becomes pregnant has a relatively low risk of SAH; however, if a woman does become pregnant the chances increase by 87%. [Our interpretation: If a BAVM is diagnosed in association with pregnancy, this will be due to hemorrhage in 87% of pts.]</td>
</tr>
<tr>
<td>Dias (1990)</td>
<td>Case-reports published between 1947-1988</td>
<td>Review of English literature including all reported cases of verified hemorrhage during pregnancy and puerperium.</td>
<td>36 pts (mean age 27 yrs) with BAVM hemorrhage during pregnancy, of whom 2 during labor and delivery. 25% of women were nulliparous. Mean GA 30 weeks. Maternal mortality 28%. Fetal mortality 14%.</td>
<td>BAVMs bleed more frequently with advancing GA, possibly due to hemodynamic changes of pregnancy. Two women with BAVMs bled during labor and delivery.</td>
</tr>
<tr>
<td>Horton et al. (1990)</td>
<td>Hospital-based retrospective case-series</td>
<td>Hospital records supplemented by written questionnaire. Annual hemorrhage rates: ratio of number of bleeds to pt-yrs during pregnancy and non-pregnant FU from birth to treatment.</td>
<td>451 women experienced 459 hemorrhages during 14,235 pt-ys, i.e. 3.2%/pt-yr. 540 pregnancies (468.6 pt-ys) occurred in 238 pts. 17 hemorrhages occurred during pregnancy, i.e. 3.6%/pt-yr. 4 (18%) in 1st trim, 7 (41%) in 2nd trim, 5 (29%) in 3rd trim and 2 (12%) in puerperium. 445 hemorrhages occurred outside pregnancy, i.e. 3.2%/pt-yr.</td>
<td>Risk of non-fatal BAVM hemorrhage during pregnancy was 3.5%/pt-yr for pts with untreated BAVMs if no history of previous hemorrhage.</td>
</tr>
<tr>
<td>Forster et al. (1993)</td>
<td>Hospital-based retrospective case-series</td>
<td>Hospital records supplemented by written questionnaire. Annual hemorrhage rates: ratio of number of bleeds to pt-yrs during pregnancy and non-pregnant FU during fertile age.</td>
<td>229 pregnancies (162 pt-ys) occurred in 116 women. 35 women never bled. 207 hemorrhages occurred during 2,431 pt-ys, i.e. 8.5%/pt-yr. 14 hemorrhages occurred during pregnancy (162 pt-ys), i.e. 8.6%/pt-yr. 3 (20%) hemorrhages occurred in 1st trim, 9 (60%) in 2nd trim, 3 (20%) in 3rd trim, but none during delivery, CS or in puerperium. Hemorrhage rate was unchanged in 3rd (5.3%/yr), 4th (5.8%/yr) trim, increased in 2nd trim (17%/yr).</td>
<td>Risk of BAVM hemorrhage is increased in 2nd trimester of pregnancy.</td>
</tr>
<tr>
<td>Gross et al. (2012)</td>
<td>Hospital-based retrospective case-series</td>
<td>Annual hemorrhage rates: ratio of number of bleeds to pt-yrs during pregnancy and non-pregnant FU during fertile age. Cox proportional hazards regression model with pregnancy as time-dependent covariate and hemorrhage as censoring event.</td>
<td>54 women – with known parturient status – experienced a total of 62 pregnancies. 4 women experienced 5 hemorrhages while pregnant. Annual hemorrhage rate during pregnancy: 11%/patient year during pregnancy time. HR for pregnancy was 3.5%/pt-yr, CI 2.6-24. One hemorrhage occurred in 2nd trim, and 4 hemorrhages occurred in 3rd trim.</td>
<td>Elevated risk of hemorrhage from BAVMs during pregnancy in comparison with non-pregnant time.</td>
</tr>
<tr>
<td>Liu et al. (2014)</td>
<td>Hospital-based retrospective analysis of prospectively collected-database</td>
<td>CCA analysis including 395 women with BAVM hemorrhage at age between 18-40 yrs</td>
<td>Six bleeds occurred in 2nd trim, 5 hemorrhages in 3rd trim, and one in puerperium. Relative rate 0.71 (95% CI 0.61-0.82).</td>
<td>Decreased risk of hemorrhage from BAVMs during pregnancy and puerperium.</td>
</tr>
<tr>
<td>Lx et al. (2010)</td>
<td>Case-reports of verified hemorrhage during pregnancy and puerperium</td>
<td>Review of English literature</td>
<td>54 pts with BAVM hemorrhage during 1st trimester (11%), 2nd trimester (44%), 3rd trim (41%), and post-partum (4%). Maternal mortality 5%. Maternal dependence 31%. Fetal mortality 2%.</td>
<td>Maternal mortality improved over time compared to previous systematic review.</td>
</tr>
</tbody>
</table>

**Table 3** Studies investigating the effect of pregnancy, delivery, and puerperium on the hemorrhage risk of BAVMs

**Author**
- Robinson et al.
- Dias
- Horton et al.
- Forster et al.
- Gross et al.
- Liu et al.
- Lx et al.

**Study population**
- Hospital-based
- Hospital-based
- Hospital-based
- Hospital-based
- Hospital-based
- Hospital-based
- Hospital-based

**Methods and analysis**
- Retrospective case-series
- Review of English literature
- Hospital records supplemented by written questionnaire.
- Hospital records supplemented by written questionnaire.
- Annual hemorrhage rates: ratio of number of bleeds to pt-yrs during pregnancy and non-pregnant FU from birth to treatment.
- Annual hemorrhage rates: ratio of number of bleeds to pt-yrs during pregnancy and non-pregnant FU during fertile age.
- Annual hemorrhage rates: ratio of number of bleeds to pt-yrs during pregnancy and non-pregnant FU during fertile age.
- Retrospective analysis of prospectively collected-database
- Review of English literature

**Results**
- Follow-up in 146 pts (96%). Group 1 (67 pts) included 24 pts (36%) with AVMs and 43 (64%) pts with aneurysms. 21/24 BAVM pts presented with SAH, and 11/21 pts bled during pregnancy. 47 pregnancies occurred in BAVM pts resulting in 35 live-born children. Group 2 (79 pts) included 9 patients (11%) with BAVMs and 70 (89%) with aneurysms. Only 1/9 BAVM pts presented with SAH. Hemorrhage usually occurred between weeks 16-24, shortly before labor, during delivery, or in early puerperium.
- 36 pts (mean age 27 yrs) with BAVM hemorrhage during pregnancy, of whom 2 during labor and delivery. 25% of women were nulliparous. Mean GA 30 weeks. Maternal mortality 28%. Fetal mortality 14%.
- 451 women experienced 459 hemorrhages during 14,235 pt-ys, i.e. 3.2%/pt-yr. 540 pregnancies (468.6 pt-ys) occurred in 238 pts. 17 hemorrhages occurred during pregnancy, i.e. 3.6%/pt-yr. 4 (18%) in 1st trim, 7 (41%) in 2nd trim, 5 (29%) in 3rd trim and 2 (12%) in puerperium. 445 hemorrhages occurred outside pregnancy, i.e. 3.2%/pt-yr.
- 229 pregnancies (162 pt-ys) occurred in 116 women. 35 women never bled. 207 hemorrhages occurred during 2,431 pt-ys, i.e. 8.5%/pt-yr. 14 hemorrhages occurred during pregnancy (162 pt-ys), i.e. 8.6%/pt-yr. 3 (20%) hemorrhages occurred in 1st trim, 9 (60%) in 2nd trim, 3 (20%) in 3rd trim, but none during delivery, CS or in puerperium. Hemorrhage rate was unchanged in 3rd (5.3%/yr), 4th (5.8%/yr) trim, increased in 2nd trim (17%/yr).
- 54 women – with known parturient status – experienced a total of 62 pregnancies. 4 women experienced 5 hemorrhages while pregnant. Annual hemorrhage rate during pregnancy: 11%/patient year during pregnancy time. HR for pregnancy was 3.5%/pt-yr, CI 2.6-24. One hemorrhage occurred in 2nd trim, and 4 hemorrhages occurred in 3rd trim.
- Six bleeds occurred in 2nd trim, 5 hemorrhages in 3rd trim, and one in puerperium. Relative rate 0.71 (95% CI 0.61-0.82).
- 54 pts with BAVM hemorrhage during 1st trimester (11%), 2nd trimester (44%), 3rd trim (41%), and post-partum (4%). Maternal mortality 5%. Maternal dependence 31%. Fetal mortality 2%.

**Conclusion**
- BAVMs were diagnosed in 36% of women who presented in association with pregnancy, which was 4 times higher than the overall numbers (9%). A BAVM pt who never becomes pregnant has a relatively low risk of SAH; however, if a woman does become pregnant the chances increase by 87%.
- BAVMs bleed more frequently with advancing GA, possibly due to hemodynamic changes of pregnancy. Two women with BAVMs bled during labor and delivery.
- Risk of non-fatal BAVM hemorrhage during pregnancy was 3.5%/pt-yr for pts with untreated BAVMs if no history of previous hemorrhage.
- Risk of BAVM hemorrhage is increased in 2nd trimester of pregnancy.
- Elevated risk of hemorrhage from BAVMs during pregnancy in comparison with non-pregnant time.
- Decreased risk of hemorrhage from BAVMs during pregnancy and puerperium.

**CCO, Case-crossover; CS, Caesarean section; GA, Gestational age; HR, Hazard ratio; PE, Pathological examination; SCCS, self-controlled case-series; Trim, Trimester**